Skip to main content

Contract Management: Observations on DOD's Financial Relationship With the Anthrax Vaccine Manufacturer

T-NSIAD-99-214 Published: Jun 30, 1999. Publicly Released: Jun 30, 1999.
Jump To:
Skip to Highlights

Highlights

Pursuant to a congressional request, GAO discussed the contractual relationship between the Department of Defense (DOD) and the BioPort Corporation for production of the anthrax vaccine, focusing on: (1) DOD's investment in BioPort's biologic facility and contracts to produce the vaccine; (2) BioPort's cash flow situation; and (3) proposals to improve the company's financial health.

Full Report

Media Inquiries

Sarah Kaczmarek
Managing Director
Office of Public Affairs

Public Inquiries

Topics

Biological warfareChemical agentsBiological agentsAnthraxChemical warfareContract administrationDefense procurementDepartment of Defense contractorsFinancial analysisImmunization services